LncRNA XIST promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by downregulating miR-27b-3p

J Biol Regul Homeost Agents. 2020 Nov-Dec;34(6):1993-2001. doi: 10.23812/20-222-A.


Chemotherapy resistance has become a major obstacle to effective treatment of human cancer. This study aimed to investigate the effect of lncRNA XIST on cell proliferation and cisplatin (CDDP) of oral squamous cell carcinoma (OSCC). RT-qPCR and Western blot analysis were used to detect mRNA and protein expression. CCK-8 and flow cytometry assays were explored to evaluate CDDP sensitivity in OSCC cells. The relationship between lncRNA XIST and miR-27b-3p was confirmed by luciferase reporter assay. The results showed that lncRNA XIST was upregulated in OSCC tissues, cell lines, and CDDP-resistant OSCC cells. Functionally, upregulation of lncRNA XIST promoted cell proliferation, enhanced CDDP resistance, and inhibited apoptosis in OSCC cells. In addition, lncRNA XIST acts as a molecular sponge for miR-27b-3p in OSCC. Downregulation of miR-27b-3p partially reversed the tumor suppression effect and CDDP chemosensitivity of XIST knockdown in CDDP-resistant OSCC cells. In conclusion, lncRNA XIST promotes cell proliferation and enhances resistance to CDDP in OSCC by downregulating miR-27b-3p.

Keywords: LncRNA XIST; cisplatin; miR-27b-3p; oral squamous cell carcinoma; proliferation.

MeSH terms

  • Cell Proliferation / genetics
  • Cisplatin / pharmacology
  • Humans
  • MicroRNAs / genetics*
  • Mouth Neoplasms* / drug therapy
  • Mouth Neoplasms* / genetics
  • RNA, Long Noncoding / genetics*
  • Squamous Cell Carcinoma of Head and Neck*


  • MicroRNAs
  • RNA, Long Noncoding
  • Cisplatin